Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation
Clicks: 191
ID: 270181
2015
Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible …
| Reference Key |
pl2015drugslenalidomide:
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | McCormack PL;; |
| Journal | drugs & aging |
| Year | 2015 |
| DOI | DOI not found |
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
animals
clinical trials as topic
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
Angiogenesis Inhibitors / therapeutic use*
prednisone / therapeutic use
antineoplastic combined chemotherapy protocols / therapeutic use
Melphalan / therapeutic use
lenalidomide
multiple myeloma / drug therapy*
thalidomide / adverse effects
thalidomide / analogs & derivatives*
pmid:25925941
doi:10.1007/s40266-015-0269-6
paul l mccormack
angiogenesis inhibitors / adverse effects
angiogenesis inhibitors / pharmacology
stem cell transplantation
thalidomide / pharmacology
thalidomide / therapeutic use
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.